0001209191-20-002167.txt : 20200106
0001209191-20-002167.hdr.sgml : 20200106
20200106202921
ACCESSION NUMBER: 0001209191-20-002167
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200102
FILED AS OF DATE: 20200106
DATE AS OF CHANGE: 20200106
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haddadin Yezan Munther
CENTRAL INDEX KEY: 0001718004
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37759
FILM NUMBER: 20511844
MAIL ADDRESS:
STREET 1: ZAHRAN STREET, 7TH CIRCLE ZAHRAN PLAZA
STREET 2: 4TH FLOOR, PO BOX 142904
CITY: AMMAN
STATE: M2
ZIP: 11844
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Outlook Therapeutics, Inc.
CENTRAL INDEX KEY: 0001649989
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 383982704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
BUSINESS PHONE: 6096193990
MAIL ADDRESS:
STREET 1: 7 CLARKE DRIVE
CITY: CRANBURY
STATE: NJ
ZIP: 08512
FORMER COMPANY:
FORMER CONFORMED NAME: Oncobiologics, Inc.
DATE OF NAME CHANGE: 20150804
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-01-02
0
0001649989
Outlook Therapeutics, Inc.
OTLK
0001718004
Haddadin Yezan Munther
C/O OUTLOOK THERAPEUTICS, INC.
7 CLARKE DRIVE
CRANBURY
NJ
08512
1
0
0
0
Stock Option (Right to Buy)
0.875
2020-01-02
4
A
0
5980
0.9853
A
2030-01-02
Common Stock
5980
5980
D
The options were granted under the 2015 Plan in lieu of $5,892.86 cash fees payable under the Issuers's non-employee Director compensation program and vest in three equal quarterly installments on the last day of each remaining fiscal quarter (3/31, 6/30 and 9/30) such that they are vested in full on September 30, 2020, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.
/s/ Lawrence Kenyon, Attorney-in-Fact
2020-01-06